Immune-related adverse events: A bibliometric analysis

被引:18
|
作者
Jiang, Shi-Tao [1 ]
Liu, Yao-Ge [1 ]
Zhang, Lei [1 ]
Sang, Xin-Ting [1 ]
Xu, Yi-Yao [1 ]
Lu, Xin [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Liver Surg, Beijing, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
immune-related adverse events; bibliometrics; VOSviewer; citespace; frontiers; RESEARCH PERFORMANCE; CHECKPOINT; BLOCKADE;
D O I
10.3389/fimmu.2022.1096806
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundDespite providing clinical benefit, immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) in a number of patients. This study explored the development pattern in irAEs research from a bibliometric perspective. MethodsWe obtained articles and reviews related to irAEs from the Web of Science Core Collection (WoSCC) (retrieved on September 13, 2022). Using the R package "Bibliometrix", the main bibliometric features were calculated, and a three-filed plot was generated to show the relationship between authors, institutions, and topics. VOSviewer was used for co-authorship and keyword co-occurrence analysis and visualization. CiteSpace was used to detect burst references and keywords. ResultsA total of 3995 publications on irAEs were included. The United States (US), Japan, and China had the highest publications. The Journal for ImmunoTherapy of Cancer had the highest number of publications. In addition to "immune-related adverse events", "immune checkpoint inhibitors", "immunotherapy", and "nivolumab" were the most frequently used keywords. ConclusionsA bibliometric analysis of 17 years of irAEs research was conducted to map a basic knowledge structure including countries, institutions, authors, journals, and publications. The findings provided a comprehensive perspective on the broad future of this research area.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Retrospective Analysis of Immune Checkpoint Inhibitors in NSCLC: Immune-Related Adverse Events and Outcomes
    Lee, A.
    Luong, M.
    Ohana, D.
    Forster, M.
    Lee, S. M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S734 - S735
  • [32] Prescreening of immune-related adverse events in our institute
    Sone, T.
    Murai, T.
    Itaya, K.
    Koike, Y.
    Ono, Y.
    Nakamura, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] Immune-related adverse events and the balancing act of immunotherapy
    Michael Conroy
    Jarushka Naidoo
    Nature Communications, 13
  • [36] Patient Voices in Rheumatic Immune-related Adverse Events
    Corps, Kara N.
    Terry, Oliver
    Lopez-Olivo, Maria A.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2024, 50 (02) : 241 - 254
  • [37] Hypersensitivity and Immune-related Adverse Events in Biologic Therapy
    Waldron, Jamie L.
    Schworer, Stephen A.
    Kwan, Mildred
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2022, 62 (03) : 413 - 431
  • [38] Clinical and translational attributes of immune-related adverse events
    Suijkerbuijk, Karijn P. M.
    van Eijs, Mick J. M.
    van Wijk, Femke
    Eggermont, Alexander M. M.
    NATURE CANCER, 2024, 5 (4) : 557 - 571
  • [39] Histologic Patterns of Immune-Related Adverse Events in the Colon
    Zhang, Mingjuan
    Neyaz, Azfar
    Shih, Angela
    Patil, Deepa
    Deshpande, Vikram
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 813 - 813
  • [40] Clinical and biological correlates of immune-related adverse events
    von Itzstein, Mitchell S.
    Sheffield, Thomas
    Burke, Michael C.
    Hsiehchen, David
    Fattah, Farjana
    Mu-Mosley, Hong
    Park, Jason Y.
    Khan, Shaheen
    Ostmeyer, Jared
    Dowell, Jonathan E.
    Homsi, Jade
    Saltarski, Jessica M.
    Gloria-McCutchen, Yvonne
    Xie, Yang
    Li, Quan-Zhen
    Wakeland, Edward K.
    Gerber, David E.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 90 - 90